United Therapeutics Corporation
UTHR
$322.94
$15.705.11%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 735.90M | 748.90M | 714.90M | 677.70M | 614.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 735.90M | 748.90M | 714.90M | 677.70M | 614.70M |
| Cost of Revenue | 75.90M | 83.10M | 77.80M | 72.90M | 71.00M |
| Gross Profit | 660.00M | 665.80M | 637.10M | 604.80M | 543.70M |
| SG&A Expenses | 164.30M | 154.10M | 177.60M | 144.40M | 131.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 374.00M | 340.70M | 395.00M | 321.40M | 353.50M |
| Operating Income | 361.90M | 408.20M | 319.90M | 356.30M | 261.20M |
| Income Before Tax | 396.50M | 388.60M | 355.30M | 398.60M | 295.40M |
| Income Tax Expenses | 95.20M | 79.50M | 77.20M | 92.00M | 78.30M |
| Earnings from Continuing Operations | 301.30M | 309.10M | 278.10M | 306.60M | 217.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 301.30M | 309.10M | 278.10M | 306.60M | 217.10M |
| EBIT | 361.90M | 408.20M | 319.90M | 356.30M | 261.20M |
| EBITDA | 381.60M | 427.30M | 338.60M | 371.30M | 274.90M |
| EPS Basic | 6.74 | 6.93 | 6.26 | 6.52 | 4.62 |
| Normalized Basic EPS | 5.63 | 6.31 | 5.01 | 5.23 | 3.58 |
| EPS Diluted | 6.18 | 6.39 | 5.85 | 6.17 | 4.35 |
| Normalized Diluted EPS | 5.17 | 5.82 | 4.68 | 4.94 | 3.38 |
| Average Basic Shares Outstanding | 44.70M | 44.60M | 44.40M | 47.00M | 47.00M |
| Average Diluted Shares Outstanding | 48.70M | 48.40M | 47.50M | 49.70M | 49.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
